Company Focus
Johnson & Johnson
Latest Johnson & Johnson News
Pharmaceutical
Donald Trump has escalated his warnings to the pharmaceutical industry with a pledge to introduce import tariffs as high as 200% on drugs produced outside the USA. The US president said companies would be granted a grace period of up to 18 months before the measure takes effect. 9 July 2025
Related News
Insights
Company Spotlight
A late-stage clinical biotechnology company pioneering physics-based therapeutic approaches to treatments.
Latest News & Features of interest to Johnson & Johnson
Pharmaceutical
Donald Trump has escalated his warnings to the pharmaceutical industry with a pledge to introduce import tariffs as high as 200% on drugs produced outside the USA. The US president said companies would be granted a grace period of up to 18 months before the measure takes effect. 9 July 2025
Biotechnology
US oncology-focused biotech Crescent Biopharma has appointed Jan Pinkas as chief scientific officer (CSO). 8 July 2025
Biotechnology
Debra Barker has been named chief medical officer (CMO) at Centauri Therapeutics, a UK immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic indications. 8 July 2025
Biosimilars
The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing US biotech major Amgen’s (Nasdaq: AMGN) denosumab brands Prolia and Xgeva, had been launched in the USA. 8 July 2025
Biotechnology
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
Biotechnology
Having appointed Renée Aguiar-Lucander as its chief executive in April and Maria Törnsén as chief operating officer a month later, Hansa Biopharma has announced the appointment of a chief medical officer (CMO). 8 July 2025
Biotechnology
US biotech Cogent Biosciences closed Monday’s trading 23% higher, following the company’s announcement of positive top-line results from the registration-directed part two of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM). 8 July 2025
Biotechnology
French biotech Nanobiotix’ (shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica, a Johnson & Johnson subsidiary. 8 July 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025
Biotechnology
The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple myeloma, according to a report on the field by DelveInsight. 7 July 2025
Latest In Brief for Johnson & Johnson
Pharmaceutical
Japan’s Nxera Pharma is to receive a $4.8 million milestone payment from UK pharma company Centessa Pharmaceuticals as part of the firms’ research collaboration. 7 July 2025
Latest Related Ones To Watch News
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
30 June 2025
17 June 2025
16 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze